.. ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer ARIAD Pharmaceuticals, Inc. today announced the initial clinical outcomes on its investigational, tyrosine-kinase inhibitor, AP26113, in sufferers with advanced non-little cell lung tumor from an ongoing Phase 1/2 trial. The scholarly research provides compelling clinical evidence of the anti-tumor activity of AP26113 at multiple dose amounts in patients with anaplastic lymphoma kinase positive NSCLC and initial clinical evidence of anti-tumor activity in patients with epidermal growth aspect receptor mutant NSCLC.In a Cox regression analysis that adjusted for variations in baseline clinical features of the patients in addition to features of the lesions and stents at baseline, the rate of restenosis was lower among individuals who received drug-eluting stents than among those who received bare-metal stents . Accordingly, to prevent one case of restenosis per year, 39 lesions would have to become treated with drug-eluting stents. Stent diameter was the most important factor contributing to the decrease in the price of restenosis with drug-eluting stents. For stents which were significantly less than 3 mm in size, the absolute rate of restenosis at 12 months was 3.6 %age points lower with drug-eluting stents than with bare-metal stents; the corresponding adjusted risk reduction was 65 percent, and the quantity needed to treat was 22.